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background: Primaryovarian insufﬁciency (POI) is characterizedbymarkedheterogeneity, butwith a signiﬁcant genetic contribution. Iden-
tifying exact causative genes has been challenging, withmany discoveries not replicated. It is timely to take stock of the ﬁeld, outlining the progress
made, framing the controversies and anticipating future directions in elucidating the genetics of POI.
methods: Asearch for original articles published up toMay2015wasperformed using PubMed andGoogle Scholar, identifying studies on the
genetic etiology of POI. Studies were included if chromosomal analysis, candidate gene screening and a genome-wide study were conducted.
Articles identiﬁed were restricted to English language full-text papers.
results: Chromosomal abnormalities have long been recognized as a frequent cause of POI, with a currently estimated prevalence of
10–13%. Using the traditional karyotype methodology, monosomy X, mosaicism, X chromosome deletions and rearrangements, X-autosome
translocations, and isochromosomes have been detected. Based on candidate gene studies, single gene perturbations unequivocally having a
deleterious effect in at least one population include Bone morphogenetic protein 15 (BMP15), Progesterone receptor membrane component
1 (PGRMC1), and Fragile X mental retardation 1 (FMR1) premutation on the X chromosome; Growth differentiation factor 9 (GDF9), Folliculo-
genesis speciﬁc bHLH transcription factor (FIGLA), Newborn ovary homeobox gene (NOBOX), Nuclear receptor subfamily 5, group A, member
1 (NR5A1) and Nanos homolog 3 (NANOS3) seem likely as well, but mostly being found in no more than 1–2% of a single population studied.
Whole genome approaches have utilized genome-wide association studies (GWAS) to reveal loci not predicted on the basis of a candidate
gene, but it remains difﬁcult to locate causative genes and susceptible loci were not always replicated. Cytogenomic methods (array CGH)
have identiﬁed other regions of interest but studies have not shown consistent results, the resolution of arrays has varied and replication is
uncommon. Whole-exome sequencing in non-syndromic POI kindreds has only recently begun, revealing mutations in the Stromal antigen
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3 (STAG3), Synaptonemal complex central element 1 (SYCE1),minichromosomemaintenance complex component 8 and 9 (MCM8,MCM9) and
ATP-dependentDNAhelicase homolog (HFM1) genes. Given the slowprogress in candidate-gene analysis and relatively small sample sizes avail-
able for GWAS, family-based whole exome and whole genome sequencing appear to be the most promising approaches for detecting potential
genes responsible for POI.
conclusion: Taken together, the cytogenetic, cytogenomic (arrayCGH) and exome sequencing approaches have revealed a genetic caus-
ation in 20–25% of POI cases. Uncovering the remainder of the causative genes will be facilitated not only by whole genome approaches in-
volving larger cohorts in multiple populations but also incorporating environmental exposures and exploring signaling pathways in intragenic and
intergenic regions that point to perturbations in regulatory genes and networks.
Key words: primary ovarian insufﬁciency / premature ovarian failure / chromosomal abnormality / gene mutation / genome-wide association
studies / whole-exome sequencing / next generation sequencing
Introduction
Primary ovarian insufﬁciency (POI), also known as premature ovarian
failure (POF) or premature menopause, is deﬁned as cessation of men-
struation before the expected age ofmenopause. This age is traditionally
deﬁned to be prior to 40 years and diagnosis is conﬁrmed by elevated
serum FSH levels (.40IU/l). Although frequently stated that 1% of
the population is affected with POI before the age of 40 years and
0.1% before age 30 years, the prevalence is actually less certain
(Coulam et al., 1986).
The disorder is clearly heterogeneous, with a wide spectrum of
causes, namely cytogenetic, genetic, infectious or iatrogenic. Auto-
immune and metabolic etiologies may or may not be genetic. Irrespect-
ive, etiology remains tobeelucidated inmost cases anduntil a decade ago
few speciﬁc causes were known beyondX-chromosomal abnormalities,
Fragile X mental retardation 1 (FMR1) premutation and FSH receptor
(FSHR) in the Finnish population (Simpson, 1975; Aittoma¨ki et al.,
1995; Wittenberger et al., 2007). Most cases of isolated POI still
appear sporadically, but 10–15% has an affected ﬁrst-degree relative,
indicating signiﬁcant genetic etiology (Van Kasteren et al., 1999). Pedi-
grees with multiple affected relatives are not rare (recessive and domin-
ant). Presenceof POI asone componentof a pleiotropic genetic disorder
is also well recognized. Yet identifying precise causative genes has been
challenging.Here,weenumerate known genetic causesof POI,most elu-
cidated within the last 5–10 years.
Confusion exists concerning nomenclature, namely the use of POF or
POI. It is the view of the authors that POI can be taken to encompass
occult, biochemical and overt stages, whereas POF is best considered
as only the ﬁnal stage of POI. The designation POI is thus best reserved
as alluding to the entire gamut of disorders having diminished ovarian
reserve—occult, subclinical, iatrogenic. Although many authors
espouse POI in lieu of POF, the canonical genetic reference—Online
Mendelian inheritance in man (OMIM)—has long used, and continues
to use POF, to nominate causative genes. These designations now
apply to POF1–POF9 (Supplementary Table SI), and the list growing.
Methods
A search for original articles published up to May 2015 was performed using
PubMed andGoogle Scholar to identify studies on genetic variants associated
with the human disease. The key word combinations include ‘premature
ovarian failure’, ‘primary ovarian insufﬁciency’, ‘early menopause’,
‘genetic’, ‘gene mutation’, ‘variant’ and ’genome wide study’. For a study to
be included in our review, it had to focus on chromosomal analysis, candidate
gene screening, or a genome-wide study in different POI cohorts. In addition,
studies on mitochondrial genes causing POI and multiple malformation syn-
dromes characterized by POI were included. Reports on the role of candi-
date genes in animal models were not included. Where appropriate,
reference lists of identiﬁed articles were also searched for further relevant
papers. However, articles identiﬁed were restricted to English language full-
text papers.
Results
Chromosomal abnormalities in POI
Chromosomal abnormalities have long been recognized as a cause of
POI, but percentages vary widely among reported series. This clearly
reﬂects biases of ascertainment, for example reﬂecting whether a
cohort was derived from a referral cytogenetic lab, a gynecologic prac-
tice, or a pediatric practice. Numerous different karyotypic anomalies
have been found, ranging from numerical defects (monosomy X; X
chromosomal mosaicism), X-deletions, X-autosome translocations,
and X-isochromosomes and other rearrangements. Aggregate fre-
quencyof chromosomal abnormalities in reported studies is summarized
in Table I. Small sample sizes as well as selection biases and differing ages
of ascertainment probably account for different prevalence in different
populations. However, each of the ﬁve largest studies with respect to
sample size reported frequencies between 10.0 and 12.9% (Zhang
et al., 2003; Lakhal et al., 2010a; Baronchelli et al., 2011; Jiao et al.,
2012; Kalantari et al., 2013); thus, a prevalence of 10–13% seems
reasonable.
Numerical defects
The X chromosome has long been known to play an essential role in the
maintenance of ovarian development and function. Females lacking an X
chromosome as well as those showing an extra X chromosome are pre-
disposed to developing POI.
45,X and 45,X/46,XX
Turner syndrome, often but not universally associated with X mono-
somy, leads to ovarian dysgenesis and accelerated follicular atresia. X
monosomy without mosaicism is more typically found in primary amen-
orrhea andcaseswerealmostuniversally understood topresentwith this
phenotype. However, many early series were recruited from pediatric
clinics, not among adult women. In 1975, Simpson (1975) reported
that 3% (5/178) of 45,X patients actually menstruated. 45,X/46,XX
and other forms of association also are associated with secondary
788 Qin et al.
amenorrhea (POI). Either haploinsufﬁciency of pivotal genes on the X
chromosome or non-speciﬁc meiotic impairment could explain the
accelerated atresia of 45,X oocytes. Variability would be expected
given potential heterozygosity of alleles in genes subjected to
X-inactivation.
47,XXX
47,XXX women may experience oligomenorrhea, secondary amenor-
rhea, and early menopause, but relative risk has not been well studied.
Goswami et al. (2003) reported the prevalence of 47,XXX in 52
women with POI to be 3.8%, whereas in our much larger Chinese
series we observed 1.5% (8/531) (Jiao et al., 2012). The presence of
three X chromosomes plausibly leads to meiotic disturbance and, sec-
ondarily, ovarian failure. Additionally, overexpression of genes that
escape X-inactivation could cause POI in 47,XXX. Mechanisms
remain to be deﬁned (Tartaglia et al., 2010). A confounder is that an as-
sociation exists between 47,XXX and autoimmune diseases (Holland,
2001; Goswami et al., 2003).
X-structural abnormalities and X-autosome translocations
Xchromosomedeletions andX-autosomebalanced translocations have
long been observed in POI andwere once the only approach available to
localize causative genes. This strategy was illustrated in the 1970s by a
region on the X chromosome appearing critical for the POI phenotype
(Sarto et al., 1973). A critical region was delineated that gave boundaries
for breakpoints of X-autosome translocations associated with ovarian
failure. This region extends from Xq13-Xq21 (POI2) to Xq23-q27
(POI1). It has been proposed by Rizzolio and colleagues that
Xq13-Xq21 governs epigenetic regulations that down-regulate
oocyte-expressed autosomal genes (Rizzolio et al., 2006, 2007, 2009).
Irrespective of mechanisms involved in the critical region, almost all
terminal deletions originating atXq13 are associatedwith primary amen-
orrhea, lack of breast development and complete ovarian failure
(Simpson and Rajkovic, 1999; Simpson, 2008). By contrast, terminal
deletions arising at Xq25 or Xq26 are characterized by the more
common phenotype being not primary amenorrhea but premature
ovarian failure. The gene designation POI1 is applied to this region.
The more distal deletions arise at Xq27 or Xq28 and exert a less
severeeffecton stature and reproductive function thandoproximaldele-
tions (Simpson, 1975; Simpson and Rajkovic, 1999). Gene(s) in this POI-
causing regionareconsidereddistinct fromFragileXmental retardation1
(FMR1), located at Xq27 and premutation of which is themost common
single cause of POI.
Multiple genes on the X chromosome have been identiﬁed by
X-autosomal translocations. These include Diaphanous-related formin
2 (DIAPH2, Xq22) (Bione et al., 1998), X-prolyl aminopeptidase (amino-
peptidase P) 2, membrane-bound (XPNPEP2, Xq25) (Prueitt et al.,
2000), Dachshund family transcription factor 2 (DACH2, Xq21.3)
(Prueitt et al., 2002), Premature ovarian failure, 1B (POF1B, Xq21.1)
(Lorda-Sanchez et al., 2000; Bione et al., 2004), Choroideremia (CHM,
Xq21.1) (Lorda-Sanchez et al., 2000; Mansouri et al., 2008), Progester-
one receptor membrane component 1 (PGRMC1, Xq24) (Mansouri
et al., 2008), Collagen, type IV, alpha 6 (COL4A6, Xq22.3) (Nishimura-
Tadaki et al., 2011) and Nuclear RNA export factor 5 (NXF5, Xq22.1)
(Bertini et al., 2010). Some will individually be discussed below.
Autosomal rearrangements
Autosomal translocations—Robertsonian and reciprocal—have been
observed in sporadic cases in Belgian, American, Japanese and Chinese
women (Hens et al., 1989; Orczyk et al., 1989; Kawano et al., 1998; Jiao
et al., 2012). Perturbations presumably confer haploinsufﬁciency or inter-
rupt pivotal genes in these regions. Non-speciﬁc defective meiotic pairing
or a position effect on contiguous genes is also a potential explanation
(Simpson, 2008; Persani et al., 2009). No autosomal region appears pref-
erentially involved, long frustrating investigators seeking tousebreakpoints
to localize regions containing autosomal genes of relevance. Searches for
autosomal regions disrupted in X-autosome translocations have similarly
not proved fruitful in identifying autosomal roles in POI.
.............................................................................................................................................................................................
Table I Frequency of chromosomal abnormalities (CA) in different population studies.
Reference Frequency of CA (%) No. of CA Sample size Clinical characteristics Population
Ayed et al. (2014) 18.0 18 100 PA, SA Tunisian
Kalantari et al. (2013) 10.05 18 179 PA, SA Iranian
Jiao et al. (2012) 12.1 64 531 PA, SA Chinese (Jinan, Beijing, Shenzhen)
Baronchelli et al. (2011) 10.0 27 269 PA, SA, EM Italian
Lakhal et al. (2010a) 10.8 108 1000 PA, SA Tunisian
Ceylaner et al. (2010) 25.3 19a 75 SA Turkish
Janse et al. (2010) 12.9 19 147 SA Dutch
Portnoi et al. (2006) 8.8 8 90 PA, SA French
Zhang et al. (2003) 12.5 13 104 POI Chinese (Chongqing)
Devi and Benn (1999) 13.3 4 30 SA American
Davison et al. (1998) 2.5 2 79 PA, SA FSH.20 IU/l English
Castillo et al. (1992) 32.0 15 47 POI Chilean
Rebar and Connolly (1990) 25.4 16 63 PA, SA American
Chromosomal ‘abnormalities’ means visible structural changes in karyotype that are sufﬁciently large to cause clinical abnormalities. Variants (e.g. prominent satellites) are not included.
CA, chromosomal abnormalities; PA, primary amenorrhea; POI, primary ovarian insufﬁciency; SA, secondary amenorrhea; EM, early menopause.
aIncluding 2 46,XY gonadal dysgenesis (Swyer syndrome).
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Single genes causing non-syndromic POI
Aside from regions of interest deﬁned by chromosome deletions and
translocations, the other traditional strategy to identify candidate
genes in POI is to study genes whose product is known and plays a
role in human folliculogenesis or shows an organ-speciﬁc effect based
on murine knockout models (candidate genes). Many genes have been
interrogated for these reasons. In this section we speciﬁcally review all
genes for which data warrant strong consideration as a candidate gene
for POI. Table II and Supplementary Table SII contain available details
of reported studies.
Variants occurring in evolutionary conserved regions are more likely
to carry functional signiﬁcance. These includemissense, nonsense, inser-
tion or deletion variants and were considered as plausible causative var-
iants with clinical signiﬁcance. Thus, perturbations should yield a severe
functional defect. A nonsense mutation that results in truncated protein
should lead to haploinsufﬁciency; a splicing site mutation or insertion/
deletion should result in a frameshift that leads to a different protein
product; a missense mutation may change the amino acid and cause a
dominant negative effect.
Those regions or genes found only by genome-wide studies, including
genome-wide association study, cytogenomic study, whole-exome se-
quencing, and next generation sequencing (NGS), are cited separately.
Genes on the X chromosome
Bone morphogenetic protein 15 (BMP15) (Xp11.2). BMP15 is located on
chromosomeXp11.2. Thepossible involvement ofBMP15 in POI patho-
genesis was initially supported by evidence from animal models. Inver-
dale and Hanna sheep with a naturally occurring Bmp15 mutation had
increased ovulation rate and twin and triplet births in heterozygotes,
but ovarian failure results from impaired follicular development beyond
the primary stage in homozygotes (Galloway et al., 2000). Bmp15 knock-
out femalemice alsowere subfertile, showing decreased ovulation rates,
reduced litter size anddecreasednumberof litters per lifetime (Yan et al.,
2001).
In humans BMP15 was ﬁrst implicated in POI by Di Pasquale et al.
(2004), who reported a heterozygous p.Y235C missense mutation in
each of two sisters having ovarian failure. The authors presented in
vitro evidence for a dominant negative mechanism. Other variants have
been identiﬁed in Caucasian, Indian and Chinese women with POI,
albeit with quite different frequencies (1.5–15%) (Di Pasquale et al.,
2006; Dixit et al., 2006c; Laissue et al., 2006; Ledig et al., 2008; Lakhal
et al., 2009, 2010b; Rossetti et al., 2009; Wang et al., 2010b). Merely
showing different frequencies between a given single nucleotide poly-
morphism (SNP) in POI and control is a less robust method than
ﬁnding a unique perturbation with functional validation in a case
(Zhang et al., 2007; Ledig et al., 2008). However, some variants found
in higher frequency indeed show marked reduction of mature protein
production (Rossetti et al., 2009).
Of relevance is that BMP15 is a member of the transforming growth
factor (TGF) family, with dimerization occurringwith otherTGFproteins
such asGDF9, to bediscussedbelow.Most reportedBMP15 variants are,
in fact, in the region corresponding to the propeptide of the protein,
which is essential for dimerization and subsequent post-translational
processing into biologically active proteins.
Progesterone receptor membrane component 1 (PGRMC1) (Xq22-q24).
PGRMC1was ﬁrst described in 1998 as a putative progesterone-binding
membrane receptor (Losel et al., 2008). This protein is expressed in
various tissues, e.g. liver, kidney, adrenal glands, uterus and leukocytes
and involves progesterone signaling in the reproductive system (Cahill,
2007; Losel et al., 2008; Mansouri et al., 2008). PGRMC1mediates pro-
gesterone’s anti-apoptotic effects on granulosa cells (Engmann et al.,
2006; Peluso et al., 2006; Losel et al., 2008; Mansouri et al., 2008).
Mansouri et al. (2008) identiﬁed amotheranddaughterwithPOI, both
of whom carried an X;autosome translocation [t(X;11)(q24;q13)]. Sys-
tematic mapping of the Xq breakpoint and performing RNA expression
studies revealed reduced expression of PGRMC1. Mutation screening of
67 femaleswith idiopathic POI identiﬁed a third patient having amissense
mutation (p.H165R), located in the cytochrome b5 domain. The
p.H165R mutation abolishes binding of cytochrome P450 7A1
(CYP7A1) to PGRMC1 and attenuates PGRMC1’s ability to mediate
the anti-apoptotic action of progesterone in ovarian cells. These ﬁndings
suggest that mutant or reduced levels of PGRMC1 may cause POI
through impaired activation of the microsomal cytochrome P450 and
increased apoptosis of ovarian cells. A recent study in Chinese patients
with POI identiﬁed a novel missense mutation (C.556C.T, p. P186S),
but there was no functional study to conﬁrm a deleterious effect
(Wang et al., 2014b).
Androgen receptor (AR) (Xq12).TheAR geneencodes theandrogen recep-
tor and is involved in sex differentiation and reproduction. Its perturb-
ation in 46,XY individuals results in the well-known sex reversed
phenotype of androgen insensitivity, testosterone produced by testis
exerting no effect on androgen-dependent differentiation. In the ovary,
AR is expressed in developing follicles, mainly granulosa cells. Deﬁciency
ofAr in femalemice results in a POI-like phenotype and dysregulationof a
number of major genes critical for folliculogenesis, indicating that normal
folliculogenesis requires AR-mediated androgen action (Shiina et al.,
2006). An association between CAG repeat length in exon 1 of the AR
gene and POI has been proposed but remains controversial (Bretherick
et al., 2008; Chatterjee et al., 2009; Sugawa et al., 2009; Panda et al.,
2010). An example is a repeat of two missense mutations (p.T650A
and p.O658K) in Indian women with POI (Panda et al., 2010).
Forkhead box O4 (FOXO4) (Xq13.1). The FOXO4 gene encodes a
member of the O class of winged helix/forkhead transcription factor
family (FOXO). FOXO4 is expressed in granulosa cells in mice and
human, and is involved in the PI3K (phosphoinositide 3-kinase)/Akt
(v-akt murine thymoma viral oncogene homolog 1)/Cdkn1b (cyclin-
dependent kinase inhibitor 1B) molecular pathway, which suggests a
functional role in ovarian physiology (Pisarska et al., 2009). Mutation
screening in 116 Tunisian patients identiﬁed only one intronic variant;
IVS2 + 41T.G; therefore, FOXO4 might not be a common cause of
POI in the Tunisian population (Fonseca et al., 2012a).
Premature ovarian failure, 1B (POF1B) (Xq21.2).Alluded to previously, this
‘gene’ is actually a region, but codiﬁed byOMIM. Its signiﬁcance is its loca-
tion within the critical POI1 region. It was found to be interrupted by a
breakpoint in an X-autosome translocation in a patient with secondary
amenorrhea (POI). Subsequent mutation analysis in an Italian POI
cohort (N ¼ 223) only revealed 30 SNPs (Bione et al., 2004). In a Leba-
nese family having ﬁve sisters with POI, Lacombe et al. (2006) established
linkage to Xq21 using whole-genome SNP typing and homozygosity-
by-descent mapping. Sequencing identiﬁed a homozygous p.R329Q
790 Qin et al.
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Table II Variants identiﬁed in candidate genes on the X chromosome for idiopathic and sporadic POI.
Gene Location Cases
(N)
Controls
(N)
Ethnicity MRa Sequence
variation
Amino acid
change
FC Mechanism Reference
BMP15 Xp11.2 50 214 Caucasian
North Africa
Asia
2 (4.0%) c.242A.G p.H81R Tiotiu et al. (2010)
c.595G.A p.G199R
100 100 Chinese 1 (1.0%) c.985C.T p.R329C Wang et al. (2010b)
300 216 Caucasian 12 (4.0%) c.13A.C p.S5R Yes Slightly affects transactivation of BRE-luc in
COV434 granulosa cells
Rossetti et al. (2009)
c.202C.T p.R68W Markedly reduces mature protein production and
affects transactivation of BRE-luc in COV434
granulosa cells
c.413G.A p.R138H
c.443T.C p.L148P
c.538G.A p.A180T No effect on protein production or
transactivation
20 93 Germany None Ledig et al. (2008)
92 76 Chinese None Zhang et al. (2007)
203 54 Caucasian
African Asian
3 (1.5%) c.443T.C p.L148P Laissue et al. (2006)
c.538G.A p.A180T
c.468G.A Sense
c.831T.C Sense
c.852C.T Sense
133 197 Indian 14 (10.5%) c.181C.T p.R61W Dixit et al. (2006c) and
Inagaki and Shimasaki
(2010)
c.182G.A p.R61E
c.226C.T p.R76C Yes Decreased mature protein production, weaker
Smad1/5/8 phosphorylation in COV434 cells
and decreased granulosa cell proliferation
c.227G.A p.R76H
c.538G.A p.A180T
c.538G.T/
c.539C.T
p.A180F/S+V
c.588T.A p.N196K
c.617G.A p.R206H Yes Decreased mature protein production, weaker
Smad1/5/8 phosphorylation in COV434 cells
and decreased granulosa cell proliferation
c.631C.T p.E211X
c.661T.C p.W221R
c.727A.G p.L243G
c.381A.G Sense
c.*40dupG 3′UTR
166 181 Caucasian 7 (4.2%) c.202C.T p.R68W Di Pasquale et al. (2004,
2006)c.538G.A p.A180T
c.704A.G p.Y235C Yes Diminished GC proliferation with a dominant
negative effect
38 51 New Zealand None Chand et al. (2006)
15 3 Japanese None Takebayashi et al.
(2000)
Continued
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mutation, which impaired the capacity to bind nonmuscle actin ﬁlaments,
and might lead to exaggerated germ-cell apoptosis and POI.
Dachshund family transcription factor 2 (DACH2) (Xq21.3). DACH2, also
named dachshund family transcription factor 2, is located on Xq21.3. It
was ﬁrst identiﬁed by ﬁne mapping of the disrupted region in an X;auto-
some translocation in POI patients (Prueitt et al., 2002). Subsequentmu-
tation screening revealed two novel missense mutations—p.R37L and
p.F316S—in an Italian cohort of POI patients (Bione et al., 2004).
However, no subsequent evidenceof involvement ofDACH2 inmamma-
lian gonads or additional mutations in other ethnic population has been
reported.
Fragile X mental retardation 1 (FMR1) (Xq27.3). One of the commonest
causes of POI is a premutation of FMR1, which when fully perturbed
(.200 CGG repeats) causes fragile X syndrome but paradoxically not
POI. A prototype of pleiotropic single gene disorders in which POI is
one component, FMR1 is discussed in the ‘Pleiotropic Single Gene Dis-
orders Having POI’ section, along with other pleiotropic genes.
Genes on autosomes
In this section we will review autosomal genes for which data appear to
warrant strong consideration as a candidate gene for POI. Supplemen-
tary Table SII contains available details on studies generating this conclu-
sion.
Growth differentiation factor 9 (GDF9) (5q31.1). Expressed in oocytes,
GDF9 is an attractive candidate gene for POI because it is, like BMP15,
a member of the TGF gene family. Increased frequencies of certain
novel variants have been detected in European, Caucasian and Asian
patients (Dixit et al., 2005; Laissue et al., 2006; Kovanci et al., 2007;
Zhao et al., 2007), but not in Japanese and New Zealand populations
(Takebayashi et al., 2000; Chand et al., 2006). All variants were hetero-
zygous. Recently, high-resolution array comparative genomic hybridiza-
tion (CGH) (2.2 kb resolution) was applied in 26 POI Swedish cases,
ﬁnding one partial GDF9 gene duplication (475 bp) (Norling et al.,
2014). Unfortunately, parents were not available to exclude a heritable
copy number variant (CNV) less likely to carry signiﬁcance. This pitfall
is discussed further in ‘Genome-Wide Studies in POI’ section.
Heterozygous changes could result in adominant negativeeffect, quite
plausible given dimerizationwith fellowmembers of the TGF gene family
(e.g. BMP15). The proportion of POI due to GDF9 perturbations is,
however, unclear. If a hydrophobic amino acid replacing a hydrophilic
amino acid were causative,GDF9 perturbations could account for a sub-
stantial number (1–4%) of POI cases.
Folliculogenesis speciﬁc bHLH transcription factor (FIGLA) (2p13.3). FIGLA,
also named factor in the germline, alpha, is a germ-cell speciﬁc, basic
helix-loop-helix (bHLH) transcription factor, that plays a crucial role in
the formation of the primordial follicle and coordinates expression of
zona pellucida genes. Zhao et al. (2008) screened 100 Chinese women
with POI and identiﬁed three variants in fourwomen:missensemutation
p.A4E in two women; deletion p.G6fsX66 in one woman, resulting in a
frameshift that leads to haploinsufﬁciency; and deletion p.140delN in a
fourth woman. Functional analyses by the yeast two-hybrid assay
demonstrated that the p.140delN mutation disrupted FIGLA binding
to the TCF3 helix-loop-helix (HLH) domain. These ﬁndings show that
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a subsetofChinesewomenwith sporadicPOIharbormutations in FIGLA.
Recently, another novel intronic variant was found in 219 Indian POI
cases (Tosh et al., 2015). Further functional validation is warranted.
Newborn ovary homeobox gene (NOBOX) (7q35). NOBOX is an oocyte-
speciﬁc homeobox gene that plays a critical role in early folliculogenesis.
The causative role was discovered by Rajkovic et al. (2004). In mice
Nobox deﬁciency disrupted early folliculogenesis and oocyte-speciﬁc
gene expression. Lack of Nobox accelerated post-natal oocyte loss and
abolished the transition from primordial to growing follicles in mice. In
female mice lacking Nobox, follicles are replaced by ﬁbrous tissue in a
manner similar to non-syndromic ovarian failure in women. Genes pref-
erentially expressed in oocytes, including Pou5f1 (POU class 5 homeo-
box 1) and Gdf9, are also down-regulated in Nobox2/2 mice.
Lechowska et al. (2011) showed that POI in Nobox deﬁcient mice
results from faulty signaling between somatic and germ line components
during embryonic development. In addition, the extremely unusual
presence of abnormal adherens junctions between unseparated
oocytes within syncytial follicles indicates that faulty communication
between somatic and germ cells is involved in, or leads to, abnormalities
in the cell adhesion program. Qin et al. (2007a) were the ﬁrst to dem-
onstrate that a perturbation (p.R355H) in NOBOX was responsible for
human POI. The mutation disrupted NOBOX homeodomain binding
toNOBOXDNA-binding element (NBE) and had a dominant negative
effect. Our functional studies demonstrated that haploinsufﬁciency was
involved in the genetic mechanism in humans for POI. Mutations in the
homeobox domain ofNOBOX proved not to be a common explanation
for POI in Chinese women (0/200) (Qin et al., 2009) but Bouilly et al.
(2011, 2015) subsequently reported that novel NOBOX loss-of-
function mutations accounted for 6.2 and 5.6%, respectively, of cases
in two large ‘primary ovarian insufﬁciency’ cohorts of Caucasian and
African ancestry.
Nuclear receptor subfamily 5, group A, member 1 (NR5A1); Steroidogenic
factor-1(SF-1) (9q33). NR5A1 encodes an orphan nuclear receptor that
regulates transcriptionof anarrayof genes involved in reproduction, ster-
oidogenesis andmale sexual differentiation. These include anti-Mullerian
hormone (AMH), Nuclear receptor subfamily 0, group B, member 1
(DAX1), Cytochrome P450, family 11, subfamily A, polypeptide 1
(CYP11A), steroidogenic acute regulatory protein (StAR), as well as
genes encoding steroid hydroxylases, gonadotrophins, and aromatase.
Inactivation ofNr5a1 speciﬁcally in mouse granulosa cells causes infertil-
ity associated with hypoplastic ovaries.
Philibert et al. (2010) identiﬁed NR5A1mutations as a frequent cause
of ‘primary amenorrhea’ in 46,XY phenotypic female adolescents with a
low testosterone concentration. Lourenco et al. (2009) sequenced
NR5A1 in four families (each having at least one family member with a
46,XY disorder of sex development and another with 46,XX POI) and
25 subjects with sporadic POI, and they identiﬁed 19 different mutations
in theNR5A1 gene. Functional studies indicated that thesemutations sub-
stantially impaired the transactivational activity of NR5A1. Subsequently
additional mutations were identiﬁed in different ethnicities with low fre-
quencies (Supplementary Table SII). Janse et al. (2012) sequenced the
coding regions of NR5A1 in a large, well-phenotyped cohort of 356
Dutch women with POI, ﬁnding 9 different mutations in 10 patients.
Functional prediction showed low to intermediate pathogenicity for all
non-conserved mutations. However, the novel p.Y5D mutation,
detected in a non-domain region, was presumed to result in haploinsuf-
ﬁciency in Chinese patients with POI (Jiao et al., 2013).
FSH receptor (FSHR) (2p21-p16). FSH/FSHR signaling plays a key role
in normal gonadal function by regulating follicular growth, estrogen
production and oocyte maturation. Mutation in FSHR was the ﬁrst
autosomal molecular explanation for POI, elucidated prior to the con-
temporary era. Aittoma¨ki (1994) and Aittoma¨ki et al. (1995, 1996)
ascertained 75 primary or secondary amenorrhea cases, and found
homozygous mutations (c.566C.T, p.A189V), in the extracellular
portion of this G-protein receptor, in women of six Finnish families
with hypergonadotrophic ovarian dysgenesis. This mutation resulted
in a dramatic reduction of binding capacity and signal transduction,
but with apparently normal ligand-binding afﬁnity (Aittoma¨ki et al.,
1995). The frequency of the c.566C.T mutation is 0.96% in a
Finnish population (Jiang et al., 1998). However, subsequent screening
in cohorts of different ethnicities seldom found mutations (da Fonte
Kohek et al., 1998; Jiang et al., 1998; Conway et al., 1999; Takakura
et al., 2001; Tong et al., 2001; Sundblad et al., 2004; Chen et al.,
2006; Ledig et al., 2008; Vilodre et al., 2008; Prakash et al., 2009;
Woad et al., 2013). Therefore, FSHR mutations are not uncommon
in XX gonadal dysgenesis in Finland, but apparently rare elsewhere
(Supplementary Table SII).
TGF, beta receptor III (TGFBR3) (1p33-p32).Human TGFBR3 is located at
1p33-p32 and encodes the TGF-beta type III receptor. The encoded re-
ceptor is amembrane proteoglycan that often functions as a co-receptor
with otherTGF-beta receptor superfamilymembers. Twomissense var-
iants, p.E459Gandp.P825L,were identiﬁed inChinesewomenwith idio-
pathic POI, both predicted to have functional and structural impacts on
the TGFBR3 protein (Qin et al., 2011). Another missense mutation—
p.P775S—was found in an Indian POI case (Dixit et al., 2006b).
G protein-coupled receptor 3 (GPR3) (1p36.1-p35). The GPR3 gene,
located in 1p36.1-p35 and having 2 exons, is a member of the G protein-
coupled receptor family. Predominantly expressed in oocytes, GPR3
maintainsmeiotic arrest in antral follicles until the LH surge throughpath-
ways involved in cAMP and cGMP regulation. In Gpr32/2 mice, the
majority of oocytes in antral follicles had unscheduled premature re-
sumption of meiosis (Mehlmann et al., 2004). A synonymous variant
(c.135G.A, p.V45V) was found in one Chinese patient (Zhou et al.,
2010), and another study also failed to ﬁnd any potential disease-
associated changes in 82 North American Caucasian women with POI
(Kovanci et al., 2008).
Wingless-type MMTV integration site family, member 4 (WNT4)
(1p36.23-p35.1). WNT4 encodes a secreted extracellular signaling
protein that is expressed in human ovaries early in fetal development
(Jaaskelainen et al., 2010), and plays a critical role in female sex determin-
ation and differentiation. In the ovaries of Wnt4 mutant mice, the rate
of apoptosis was similar to that of wild type mice at birth; however,
apoptotic cells progressively increased during follicular development
(Jaaskelainen et al., 2010). By sequencing the coding region of WNT4
in 55 Tunisian women with POI, a synonymous variant in exon 2
(c.99G.A, p.S33S) was identiﬁed (Lakhal et al., 2012). Mutational ana-
lysis was also performed in 145Chinesewomenwith POIwith no causa-
tive variants found (Chen et al., 2011b).
Genetics of primary ovarian insufﬁciency 793
Inhibins: inhibin, alpha (INHA) (2q35); inhibin, beta A (INHBA) (7p15-p13);
inhibin, beta B (INHBB) (2cen-q13). Inhibin is a dimeric glycoprotein
hormone. Belonging, like BMP-15 and GDF9, to the superfamily of
TGF-b, inhibin is a negative regulator of FSH. Inhibin encompasses
inhibin, alpha (INHA) (2q35), inhibin, beta A (INHBA) (7p15-p13), and
inhibin, beta B (INHBB) (2cen-q13).
The missense mutation c.769G.A (p.A257T) in the INHA gene
was more frequently found in patients with POI in New Zealand (7%)
(Shelling et al., 2000), India (11.2%) (Dixit et al., 2004) and Italy (4.5%)
(Marozzi et al., 2002). Increased susceptibility to POI was associated
with impaired inhibin B bioactivity (Chand et al., 2007). The additional
novel missense mutations c.275G.A (p.S92N), c.525C.G
(p.H175Q) and c.545C.A (p.A182D) were exclusively identiﬁed in
Indian POI patients (1.25% for each mutation) (Dixit et al., 2006a). It is
unclear whether polymorphisms in the INHA promoter result in
reduced inhibin expression, but thepromoter variant c.-16C.Twas sig-
niﬁcantly under-represented inpatientswithPOI inNewZealand (Harris
et al., 2005). The INHBA and INHBB gene encode inhibin bA and inhibin
bB subunits. Causative mutations were not found in the two genes,
however, except possibly for one synonymous mutation c.1032C.T
in the INHBA gene (Shelling et al., 2000; Chand et al., 2010).
POU class 5 homeobox 1 (POU5F1) (6p21.31). The POU5F1 transcription
factor gene, located on 6p21.31, is signiﬁcantly down-regulated inNobox
knockout mice. Thus, POU5F1 becomes a potential candidate gene for
POI, a downstream target of NOBOX. Wang et al. (2011) sequenced
175 Chinese POI cases and found one non-synonymous variant
(p.P13T), a heterozygous hydrophobic to hydrophilic substitution.
MutS homolog 4 (MSH4) (1p31) and MSH5 (6p21.3). MSH4 and MSH5
belong to the DNA mismatch repair gene family, playing pivotal roles
in meiotic recombination. Mammalian MSH4 and MSH5 proteins form
a heterodimeric complex and exert essential functions for normal
chromosome synapsis during zygotene. Disruption of Msh4 or Msh5 in
female mice resulted in sterility, degenerated ovaries and progressive
loss of oocytes due to meiotic failure (de Vries et al., 1999; Kneitz
et al., 2000). In a case–control study in a Caucasian population, in
which both genes were sequenced, a heterozygous mutation p.P29S in
MSH5 was found in 2 of 41 cases. The mutation was located in the
Hmsh4-binding domain of MSH5 which could disrupt the integrity of
the protein interaction between MSH5 and MSH4 (Mandon-Pepin
et al., 2008).
Forkhead box O3 (FOXO3) (6q21). Forkhead transcription factor FOXO3,
located at 6q21, encodes a master regulator and potent suppressor of
primordial follicle activation. Loss of Foxo3 function in mice leads to
POI due to global follicle activation (Liu et al., 2007). The frequency of
variants in POI patients differs in different ethnic groups (Supplementary
Table SII), but in several populations the frequencies of FOXO3 variants
are not insigniﬁcant (6% in French and 13.3% in Chinese). However, the
pathological role of these variants needs to be determined by functional
studies.
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal
domain, 2 (CITED2) (6q23.3). CITED2 is essential for early embryonic de-
velopment. This is evidenced by delayed differentiation of gonads in
Cited22/2mice (Combes et al., 2010). Fonseca and colleagues reported
a novel missense mutation p.P202T in one of 116 Tunisian POI cases
(Fonseca et al., 2012b). Further studies in other populations are
warranted.
Spermatogenesis and oogenesis speciﬁc basic helix-loop-helix transcription
factor 1 (SOHLH1) (9q34.3) and SOHLH2 (13q13.3). As germ cell
speciﬁc master-master transcription factors, SOHLH1 and SOHLH2
orchestrate different oocyte-speciﬁc genes essential for early folliculo-
genesis. Sohlh1/2-deﬁcient mice exhibit atrophied ovaries devoid of
follicles due to defective primordial-to-primary follicle transition
(Pangas et al., 2006; Choi et al., 2008). Novel distinct heterozygous var-
iants were identiﬁed in both SOHLH1 and SOHLH2 in large cohorts of
women with POI of Han Chinese and Serbian origin (Qin et al., 2014a;
Zhao et al., 2015). Plausible pathogenesis might involve disturbing
the expression, transactivation or homo-/hetero-dimerization of
SOHLH1 or SOHLH2 proteins. No subsequent reports exist, to our
knowledge.
Phosphatase and tensin homolog (PTEN) (10q23.3). Localized on chromo-
some 10q23.3, PTEN plays a causative role in early activation of primor-
dial follicles by negatively regulating the PI3K pathway (Reddy et al.,
2008). Primordial follicles become depleted in Pten null mice in early
adulthood, mimicking the phenotype of POI in humans. However, no
causative mutation was detected in coding regions of PTEN gene in
Japanese and Chinese women with POI (Shimizu et al., 2009; Zhao
et al., 2011).
Nanos homolog 1, 2, 3 (Drosophila) (NANOS1, 10q26.11; NANOS2,
19q13.32; NANOS3, 19p13.13). The NANOS gene family is known to
be required for primordial germ cell (PGC) development and mainten-
ance. Three homologs (NANOS1,NANOS2 andNANOS3) exist. Disrup-
tion of Nanos1 in mice did not affect germ cell development, but
knockout of Nanos2 or Nanos3 resulted in infertility with decreased
gonad size due to loss of PGC.Nanos2 deﬁciency only resulted in sperm-
atogonia losswhereasNanos3 impaired PGCmaintenance in bothmales
and females (Tsuda et al., 2003).
Mutations inNANOS3were investigated in 80 Chinese and 88 Cauca-
sian women with POI (Qin et al., 2007b). No causative mutations were
found in coding exons. However, one potentially relevant heterozygous
mutation (c.457C.T; p.R153W)was identiﬁed in another study involv-
ing 100 Chinese POI patients (Wu et al., 2013). Functional studies
showed decreased stability of NANOS3, potentially resulting in a hypo-
morph. And a homozygous mutation (c.358G.A, p.E120K) was found
in two sisters with primary amenorrhea from 85 Brazilian women with
POI. In vitro and in silico functional studies revealed that this mutation
impaired the ability of NANOS3 to prevent apoptosis, suggesting a
mechanism for POI involving increasedPGCapoptosis during embryonic
cell migration (Santos et al., 2014). Taken together, these results suggest
a role for NANOS3mutation in some cases of POI.
Cyclin-dependent kinase inhibitor 1B (CDKN1B) (12p13.1-p12). CDKN1B,
also known as P27 andKIP1, encodes a cyclin-dependent kinase inhibitor
that regulates proliferation and differentiation in many tissues. It sup-
presses ovarian follicle endowment and activation, and promotes follicle
atresia. Premature follicle depletion occurred due to accelerated activa-
tion inCdkn1b knockoutmice (Rajareddy et al., 2007). Sequence analysis
of CDKN1B found one novel heterozygous mutation c.356T.C
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(p.I119T) in one of 87 Tunisia POI patients (Ojeda et al., 2011).
However, no variants were identiﬁed in Chinese cohorts (Wang et al.,
2010a; Zhao et al., 2013), suggesting that mutations in CDKN1B are
not common in POI, at least in this population.
Anti-Mullerian hormone receptor, type II (AMHR2) (12q13). AMHR2
encodes a receptor in the AMH pathway which plays a crucial role in
the development and maintenance of reproductive organs in
mammals. Polymorphism c.-482 A.G (rs2002555) in AMHR2 was
revealed to be associated with age at menopause in interaction with
parity in Dutch women, but no association was found with POI in
Korean andChinesewomen (Yoon et al., 2013;Qin et al., 2014b).Nega-
tive results in AMHR2 were also reported in 16 Japanese women with
POI (Wang et al., 2002). However, Qin et al. (2014b) identiﬁed two
novel missense mutations (p.I209N and p.L354F) in a cohort of
Chinese POI women.
KIT ligand (KITLG) (12q22). The human KITLG gene, located at 12q22,
encodes the ligand of a tyrosine-kinase receptor. KIT/KITLGplays a crit-
ical role during oogenesis and folliculogenesis. Mice with a deﬁciency in
Kitlgmanifested impaired PGCs (Matsui et al., 1991). However, no per-
turbations were reported in the coding region of KITLG from 40 Cauca-
sian POI patients (Hui et al., 2006).
Forkhead box O1 (FOXO1) (13q14.1). FOXO1, another member of the
forkhead family of transcription factors, is important in granulosa cell
function and follicle maturation. Watkins et al. (2006) identiﬁed one
5′UTR mutation (c.-30C.T) and one missense mutation (p.P84L) in
60 New Zealand and Slovenia POI patients.
Spalt-like transcription factor4 (SALL4) (20q13.2). SALL4, a zinc ﬁnger tran-
scription factor, is expressed inmurineoocytes. SALL4binds toPOU5F1
and could regulate its expression. Both Sall4 and Pou5f1 are drastically
down-regulated in Nobox2/2 newborn ovaries (Zhang et al., 2006;
Choi et al., 2007). Wang et al. (2009) screened the coding regions of
SALL4 in 100 Han Chinese females with non-syndromic POI and identi-
ﬁed two heterozygous missense mutations (p.V181M and p.T817A) in
the conserved region. These may or may not be POI-associated gene
variants. Further studies are needed to determine the functional effect
of these variants.
Meiotic protein covalently bound to DSB (SPO11) (20q13.31). SPO11 is
involved inmeiosis, forming thedouble-strandbreaks (DSBs) that initiate
meiotic recombination. Spo112/2 mice are infertile with premature de-
pletion of oocyte because of defective meiosis. However, no novel var-
iants were found in 41 women with non-syndromic POI (Mandon-Pepin
et al., 2008). It is not clear whether an association between SPO11 mu-
tation and sporadic POI exists in human.
DNAmeiotic recombinase 1 (DMC1) (22q13.1).Genes perturbingmeiosis
are logical candidates for non-syndromic POI.DMC1 encodes amember
of the superfamily of recombinases, which are important for repairing
double- strand DNA breaks during mitosis and meiosis. Among 41
French women with POI, Mandon-Pepin et al. (2008) found one POI
case with homozygous mutation p.M200V. However, a subsequent
screening revealed no mutation but two known SNPs in 192 Chinese
women with POI (Wang et al., 2012).
Pleiotropic single gene disorders in POI
Distinct from non-syndromic POI, pleiotropic Mendelian disorders may
manifest POI as part of their phenotypic spectrum. Indeed, the most
common single genetic explanation for POI is represented by such a dis-
order—premutation for fragile X syndrome (Table III).
Fragile X syndrome: familial mental retardation 1 (FMR1) (Xq27.3)
Perturbations of FMR1 are responsible for fragile X syndrome. Clinical
features include mental retardation, characteristic facial features with
large ears and prominent jaw, connective tissue ﬁndings ( joint laxity),
large testes after puberty, and behavioral abnormalities. Fragile X syn-
drome occurs in males when CGG repeats number above 200. In
females70%ofwomenwith.200CGGrepeats show intellectual dis-
ability (deVries et al., 1996). The incidenceof fragileX syndrome inmales
is approximately 1 in 4000, and in females 1 in 8000 (ACOG committee
opinion, 2006a)
Thenormal numberofCGGrepeats in FMR1 is 32.Thereafter, there is
a stage (premutation) in which 54–200 CGG repeats exist. Pathogenic
effects including mental retardation and ataxia may exist, as well as
POI. About 15–20% of women with a FMR1 premutation develop
POI (Wittenberger et al., 2007). Conversely, 5% of sporadic cases and
10–15% of familial cases in the Caucasian population are explained by
FMR1 premutations. For reasons that are not clear, the number of
CGG repeats signiﬁcantly correlateswith risk of POI onlywithin selected
ranges. There is only a slightly increased riskof expansion associatedwith
40–79 repeats; but higher risk with 80–99 repeats, yet no further
increased risk occurs after .100 repeats, and as noted POI is not
observed with the full mutation (.200 CGG) (Allingham-Hawkins
et al., 1999). One possible explanation is that certain genes are sup-
pressed in the 54–100 premutation range and link to POI, whereas
other genes become suppressed only with higher numbers of CGG
repeats. Perhaps, then, phenotypes in the two groups differ because
some ovarian genes are inhibitory and others are the converse. Thus,
ovarian function may be initially suppressed but later return to normal
function.
Given the comparatively higher frequency of premutation of FMR1 in
POI than the general population (Supplemental Table SIII), FMR1 testing
has become part of the work-up for women with POI. It is formally
recommended in Europe (Foresta et al., 2002; European Society of
HumanGenetics; European SocietyofHumanReproduction andEmbry-
ology, 2006b). In other populations the prevalence is lower. Guo et al.
(2014) reported thatonly 2premutation carrierswere found in379spor-
adic Chinese POI cases (0.49%); none were found in 402 controls. The
frequency in Chinese women is thus considerably lower than in Cauca-
sian women (3.3–6.7%). Frequencies are 1.56% in Japanese (Ishizuka
et al., 2011) and 4.8% in Slovenian women (Gersak et al., 2003).
Blepharophimosis-ptosis-epicanthus syndrome (BPES): forkhead box
L2 (FOXL2) (3q23)
Blepharophimosis-ptosis-epicanthus syndrome (BPES) is a pleiotropic
autosomal dominant syndrome inwhich FOXL2 is perturbed and prema-
ture ovarian failure occurs (Crisponi et al., 2001). That FOXL2 plays a key
if not the pivotal role in ovarian development initially came from study of
BPES kindreds. More than one hundred unique FOXL2 mutations have
now been described in BPES in different populations (Beysen et al.,
2004). By contrast, constitutional mutations are uncommon but
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Table III Candidate genes responsible for Mendelian disorders that manifest POI.
Gene Location Mendelian syndrome Somatic features Reference
FMR1 Xq27.3 Fragile X syndrome Attention deﬁcits, hyperactivity, social deﬁcits, anxiety disorder, deﬁcits in cognitive
ﬂexibility.
Reiss andHall (2007) andSpath et al. (2010)
FOXL2 3q23 Blepharophimosis-ptosis-epicanthus BPE type
I syndrome, BPES I
BPES type I is a complex eyelid malformation associated with POI. The major features of
the eyelid malformation involve (i) narrowed horizontal aperture of the eyelids
(blepharophimosis), (ii) drooping of the upper eyelid (ptosis), (iii) the presence of a fold of
skin arising from the lower eyelid that runs inward and upward (epicanthus inversus), and
(iv) lateral displacement of the inner canthi (telecanthus).
Zlotogora et al. (1983) and Oley and
Baraitser (1988)
GALT 9p13 Galactosemia Cataracts, speech defects, poor growth, poor intellectual function, neurologic deﬁcits
(predominantly extrapyramidal ﬁndings with ataxia).
Schadewaldt et al. (2004)
AIRE 21q22.3 Autoimmune
polyendocrinopathy-candidiasis-ectodermal
dystrophy syndrome, APECED
Candidiasis, Addison’s disease, hypoparathyroidism, type 1 diabetes, alopecia, vitiligo,
ectodermal dystrophy, celiac disease and other intestinal dysfunctions, chronic atrophic
gastritis, chronic active hepatitis, autoimmune thyroid disorders, pernicious anemia.
Fierabracci et al. (2012)
EIF2B EIF2B2
-14q24.3;
EIF2B4-
2p23.3; EIF2B5-
3q27.1
Central nervous system leukodystrophy and
ovarian failure, ovarioleukodystrophy
Neurological disorder characterized by involvement of the white matter of the central
nervous system. When Leukodystrophies associated with premature ovarian failure
referred to as ovarioleukodystrophy.
Mathis et al. (2008)
POLG 15q25 Progressive external ophthalmoplegia, PEO Manifestations range from involvement limited to the eyelids and extraocular muscles. Graziewicz et al. (2007)
NOG 17q22 Proximal symphalangism, SYM1 Ankylosis of the proximalinterphalangeal joints. Kosaki et al. (2004)
PMM2 16p13 PMM2-CDG CDG-1 (a previously known as
congenital disorder of glycosylation type 1a)
Cerebellar dysfunction (ataxia, dysarthria, dysmetria), non-progressive cognitive
impairment, stroke-like episodes, peripheral neuropathy with or without muscle wasting,
absent puberty in females, small testes inmales, retinitis pigmentosa, progressive scoliosis
with truncal shortening, joint contractures, and premature aging
Sparks and Krasnewich (2005)
HSD17B4
HARS2
CLPP
LARS2
C10orf2
5q21
5q31.3
19p13.3
3p21.3
10q24
Perrault syndrome, PS Sensorineural deafness in bothmales and females, andneurologicalmanifestations in some
patients.
Jenkinson et al. (2013),Morino et al. (2014),
Pierce et al. (2011), Pierce et al. (2013) and
Pierce et al. (2010)
BLM 15q26.1 Bloom syndrome Chromosomal breakage leading to early onset of aging, short stature and elevated rates of
most cancers.
Ellis and German (1996)
ATM 11q22-q23 Ataxia telangiectasia, A-T Progressive cerebellar degeneration, telangiectasias, immunodeﬁciency, recurrent
infections, insulin-resistant diabetes, premature aging, radiosensitivity, and high risk for
epithelial cancers in surviving adults.
Gatti et al. (1991) and Su and Swift (2000)
WRN 8p12 Werner syndrome Premature aging of the skin, vasculature, and bone and elevated rates of certain cancers,
particularly sarcomas.
Epstein et al. (1966)
RECQL4 8q24.3 Rothmund–Thomson syndrome, RTS Cutaneous rash, sparse hair, small stature, skeletal and dental abnormalities, cataracts,
premature aging, and an increased risk for cancer, especially malignancies originating from
bone and skin tissue.
Wang et al. (2001)
FMR1: Fragile X mental retardation 1; FOXL2: forkhead box L2; GALT: galactose 1-phosphate uridyl transferase; AIRE: autoimmune regulator; EIF2B: eukaryotic translation initiation factor; POLG: polymerase (DNA directed), gamma; NOG:
noggin; PMM2: Phosphomannomutase 2; HSD17B4: Hydroxysteroid (17-beta) dehydrogenase 4; HARS2: Histidyl-tRNA synthetase 2, mitochondrial; CLPP: caseinolytic mitochondrial matrix peptidase proteolytic subunit; LARS2: leucyl-tRNA
synthetase 2, mitochondrial; C10orf2: Chromosome 10 open reading frame 2; BLM: Bloom syndrome, RecQ helicase-like; ATM: ATM serine/threonine kinase; WRN: Werner syndrome, RecQ helicase-like; RECQL4: RecQ protein-like 4.
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reported in non-syndromic POI. Perhaps 2–3% of isolated POI cases
have a FOXL2mutation (De Baere et al., 2002; Harris et al., 2002) (Sup-
plementary Table SII).
Galactosemia: galactose 1-phosphate uridyl transferase (GALT)
(9p13)
Galactosemia is caused by deﬁciency of galactose 1-phosphate uridyl
transferase (GALT). Ovarian failure is a common long-term complica-
tion in girls and women with galactosemia, ﬁrst described by
Kaufman and coworkers (Kaufman et al., 1979, 1981), who observed
POI in 12 of 18 (67%) galactosemic women. Later Waggoner et al.
(1990) reported that 17% (8/47) galactosemic women presented
with ovarian failure. However, with regard to duarte galactosemia, a
mild variant of GALT deﬁciency, no apparent ovarian dysfunction was
reported (Badik et al., 2011). Pathogenesis involves excess galactose
toxicity that impairs folliculogenesis, induces resistance to gonadotro-
phins and accelerates follicular atresia (Fridovich-Keil et al., 2011;
Banerjee et al., 2012).
Carbohydrate-deﬁcient glycoprotein syndrome type I (CDG-Ia):
phosphomannomutase 2 (PMM2) (16p13)
In type 1 carbohydrate-deﬁcient glycoprotein deﬁciency, also named
phosphomannomutase deﬁciency, mannose-6-phosphate cannot be
converted to mannose-1-phosphate. This lipid linked oligosaccharide
is necessary for formation of secretory glycoproteins.Neurologic abnor-
malities and ovarian failure occur (deZegher and Jaeken, 1995; Kristians-
son et al., 1995). Located on 16p13, PMM2 is typically caused by a
missense mutation (Bjursell et al., 1997).
Proximal symphalangism (SYM1) and multiple synostoses syndrome
(SYNS1): noggin (NOG) (17q22)
NOG encodes a secreted polypeptide that binds to and inactivates
members of the TGF-b superfamily (i.e. BMP2, 4, 7, 14 and GDF5).
NOG is expressed in various tissues including female reproductive
organs. NOG mutations are known to explain proximal symphalangism
(SYM1) and multiple synostoses syndrome (SYNS1) (Gong et al.,
1999). In addition, Kosaki et al. (2004) described a heterozygous muta-
tion (p.E48K) in NOG in a female presenting with SYM1 and also having
POI. However, Laissue et al. (2007) concluded the relationship between
NOGmutations and non-syndromic POI was not clear, having screened
thecoding sequenceofNOG in 100non-syndromic sporadicPOIpatients
and identifying only one heterozygous mutation (p.G92E) (Supplemen-
tary Table SII). Actually this experience mirrors the situation involving
other pleiotropic genes causing POI.
Autoimmune regulation/autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED):
autoimmune regulator (AIRE) (21q22.3)
The AIRE gene can if perturbed lead to multi-system abnormalities: alo-
pecia, vitiligo, keratopathy,malabsorption, hepatitis andmucocutaneous
candidiasis. Ovarian hypoplasia often occurs, usually in the third decade
(Wang et al., 1998). Many different AIRE perturbations have been found
in this autosomal dominant disorder, not only nonsense mutations but
also frame shifts. No particular mutation leads to ovarian failure as dis-
tinct from other autoimmune phenomena. AIRE mutations have not
yet been sought in women with isolated POI (non-syndromic).
Ovarian leukodystrophy: eukaryotic translation initiation factor
(EIF2B): subunit 2 beta, 39 kDa (EIF2B2) (14q24.3); subunit 4 delta,
67 kDa (EIF2B4) (2p23.3); subunit 5 epsilon, 82 kDa (EIF2B5)
(3q27.1)
‘Vanishing white matter’ leads to variable but progressive neurological
degeneration. Ovarian failure may coexist (Schiffmann et al., 1997;
Boltshauser et al., 2002). That the causative gene (EIF2B) allows
denatured stress-related proteins to accumulate makes plausible the
relevance to oogenesis, given ongoing oocyte degeneration. Fogli et al.
(2003) found variants in EIF2B2, EIF2B4 and EIF2B5 in seven POI cases
with neurologic abnormalities, but in 93 non-syndromic POI none
were found positive (Fogli et al., 2004). Therefore, EIF2B genes have
not yet been shown to be responsible for non-syndromic POI.
Perrault syndrome: hydroxysteroid (17-beta) dehydrogenase 4,
HSD17B4, 5q21; histidyl-tRNA synthetase 2, mitochondrial,
HARS2, 5q31.3; leucyl-tRNA synthetase 2, mitochondrial, LARS2,
3p21.3; caseinolytic mitochondrial matrix peptidase proteolytic
subunit, CLPP, 19p13.3; chromosome 10 open reading frame 2,
C10orf2, 10q24
Perrault syndrome is a well-recognized pleiotropic autosomal recessive
disorder characterized by ovarian failure in females, progressive sensori-
neural deafness in both males and females, and in some patients, neuro-
logical manifestations. Only recently have the underlying genes been
identiﬁed andproved tobeheterogeneous. In a familyofmixedEuropean
ancestry with two sisters presentingwith Perrault syndrome, compound
heterozygous variants - c.650A.G (p.Y217C) and c.1704T.A
(p.Y568X), in HSD17B4 were found. Then with similar genomic strat-
egies with linkage analysis or whole-exome sequencing (WES), muta-
tions in HARS2, LARS2, CLPP and C10orf2 have been found in the
context of Perrault syndrome (Pierce et al., 2011, 2013; Jenkinson
et al., 2013; Morino et al., 2014). All these genes are essential for
normal mitochondrial function. This group of causative genes is detailed
in ‘Mitochondrial Genes Causing POI’ Section.
Other pleiotropic disorders
Table III lists other nuclear genes causing syndromes in which POI is a
feature. These include POLG associated with progressive external oph-
thalmoplegia (PEO, detailed in ‘Mitochondrial Genes Causing POI’
section), BLM with Bloom syndrome, AIRE with Ataxia telangiectasia,
WRN with Werner syndrome and RECQL4 with Rothmund–Thomson
syndrome. A common feature of several is chromosomal breakage,
best exempliﬁed by Bloom syndrome (Simpson and Elias, 2003;
Simpson, 2014).
In aggregate these and other conditions in Table III explain no more
than 1% of cases of POI. From a scientiﬁc perspective however, elucidat-
ing the role these genesplay in reproductionoffers novel clues to integrity
needed for normal ovarian differentiation. Clinicians caring for females
with these syndromes should thoroughly investigate and evaluate any
reported menstrual irregularities.
Mitochondrial genes causing POI
Perturbationsofmitochondrial genesornuclear genes affectingmitochon-
dria are goodcandidates for POIbecause thematureoocytehas the great-
est number of mitochondria of any human cell. Mature oocytes readily
accumulate mitochondria during oogenesis, mitochondrial biogenesis
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playing an essential role in oocytematuration, fertilization and embryo de-
velopment. Dysregulation of mitochondrial dynamics contributes to
excess oxidative stress and initiation of apoptosis, thus accelerating follicle
depletion. A marked quantitative decrease of mitochondrial DNA (mt
DNA) in oocytes and peripheral blood cells has been well documented
in women with ovarian insufﬁciency (May-Panloup et al., 2005; Bonomi
et al., 2012). Thus, any gene affecting mitochondria involving muscular
and neurological disturbance is a candidate, because these systems are
so dependent on mitochondrial integrity. Genes governing mitochondrial
functions may be located in the nucleus, like those discussed in ‘Single
Genes Causing Non-syndromic POI’ section, or in mitochondria itself
(mt DNA). To date, those of relevance to POI have been nuclear genes.
Progressive external ophthalmoplegia (PEO): polymerase (DNA
directed), gamma (POLG) (15q25)
mtDNA mutations usually affect muscular and neurological systems. In
progressive external ophthalmoplegia (PEO) clinical features are prox-
imalmyopathy, sensoryataxia andparkinsonism.The causativemutation
lies in thegeneencodingpolymerasegamma(POLG),which is responsible
for mtDNA replication and repair. In three of seven families studied by
Luoma et al. (2004), POI cosegregated with PEO. A p.Y955C mutation
in POLG was found in two of these three families. p.Y955C (tyrosine to
cytosine) affects a highly conserved region, rending functional plausibility.
Compound heterozygosity (N468D/A1105T) was observed by Pagna-
menta et al. (2006) in another 3-generation family inwhichmultiple family
members were affected with both PEO and POI. Mutation screening of
POLG in isolated POI, has, however, yielded few perturbations. A single
p.R953C mutation was found in 201 POI cases (0.5%) cumulatively
reported by Tong et al. (2010). No novel mutations were identiﬁed in
Italian and British women with POI (Pagnamenta et al., 2006; Bonomi
et al., 2012; Duncan et al., 2012) (Supplementary Table SII). Therefore,
POLG variation is not a common explanation for sporadic POI in the
absence of clinical suspicion for other mitochondrial-associated physical
signs.
Perrault syndrome:HARS2, 5q31.3; LARS2, 3p21.3; CLPP, 19p13.3;
C10orf2, 10q24
As reviewed in ‘Pleiotropic Single Gene Disorders Having POI’ Section,
ovarian failure is oneof the characterized features in Perrault syndrome in
females.Thegenes listedencodemitochondrial tRNAsynthetase, cham-
bered protease and primase-helicase and have been found to harbor
mutations responsible for POI in Perrault syndrome (Pierce et al.,
2011, 2013; Jenkinson et al., 2013; Morino et al., 2014). Through WES
in a consanguineous Palestinian family and a nonconsanguineous Sloven-
ian family with Perrault Syndrome, homozygous mutation c.1565C.A
(p.T522N) and compound heterozygous mutation c.1077delT and
c.1886C.T (p.T629M) in the LARS2 gene were identiﬁed, respectively
(Pierce et al., 2013). WES was also performed in a nonconsanguineous
family of mixed European ancestry, showing compound heterozygous
mutations c.598C.G (p.L200V) and c.1102G.T (p.V368L) in the
HARS2 gene (Pierce et al., 2011). The homozygous mutations
c.433A.C (p.T145P), c.440G.C (p.C147S) and c.270+4A.G in
the CLPP gene were observed in three consanguineous Pakistani families
with Perrault Syndrome (Jenkinson et al., 2013). In a Japanese family,
affected individuals carried compound heterozygous p.R391H and
p.N585S in the C10orf2 gene essential for replication of mtDNA; mean-
while compound heterozygous mutations p.W441G and p.V507I were
responsible for this disease in another family of European ancestry
(Morino et al., 2014).
In aggregate, the above supports a critical role for genes controlling
mitochondria in the maintenance of ovarian function and their roles in
non-syndromic POI warrant further investigation.
Multiple malformation syndromes
characterized by POI
In other syndromes, POI or primary ovarian failure (gonadal dysgenesis)
is acceptedasonecomponentbut thecausative genehasnotbeen found.
Supplementary Table SIV lists these conditions. Of particular interest is
POI associated with cerebellar ataxia (Simpson, 2013).
Genome-wide studies in POI
Contemporary genetic strategies applied to locate susceptible loci or
genes causing POI have extendedbeyond suspected candidate gene inter-
rogations to genome-wide approaches. Approaches include linkage ana-
lysis in families with multiple affected members, CGH for CNV,
genome-wide association studies (GWAS), genome-wide sequencing of
exomes (WES) and, in the future, whole genome sequencing (WGS).
GWAS
InGWAS, also known aswhole genome association study (WGAS), one
examines many common genetic variants in different individuals to see if
any variant is associated with a trait. In GWAS one searches agnostically
through the entire genome to identify variants (SNPs) more common in
cases than controls of similar ethnicity. No a priori expectations exist. Six
GWAS have been performed to identify variants associated with POI,
but not all adhered to accepted criteria. Sample sizes were often very
small and replicates not sought (Table IV). The ﬁrst GWAS showed as-
sociation with the PTH-responsive B1 gene (PTHB1) in a small discovery
set of 24 women and 24 controls (Kang et al., 2008). Knauff et al. (2009)
identiﬁed an association of an intron SNP in ADAM metallopeptidase
with thrombospondin type1motif, 19 (ADAMTS19)with POI in a discov-
ery set of only 99 Dutch women and 181 controls; no replication set
existed. Laminin, gamma1 (LAMC1) was then reported to be signiﬁcantly
associatedwithPOI inKorea in122cases versus242controls (Pyun et al.,
2012).
Our group conducted the largestGWASwith an initial discovery set of
391 cases versus 895 controls; the independent replication set consisted
of 400 cases and 800 controls. The most signiﬁcant association was at
8q22.3 (1.6 × 1026–3.86 × 1026). This falls short of the canonical
1028 expected to confer unequivocal signiﬁcance. This region does
not contain a protein coding candidate gene (Qin et al., 2012b).
However, it is now appreciated that 90% of signiﬁcant GWAS associa-
tions are in intragenic or intergenic regions, portions of the 98.5% of
the genome not coding for protein. These regions include a host of regu-
latory genes and networks (ENCODE). 8q22.3may be an important yet
undeﬁned long-distance regulatory region affecting ovarian differenti-
ation and oogenesis. Disruption might lead to ovarian failure, analogous
to disruption of the region upstream of Sex determining region Y-box 9
(SOX9) that causesXY sex reversal inmice and humans (Qin et al., 2003,
2004). Replication in independent cohorts needs to be performed to de-
termine potential causative roles.
GWAS have revealed multiple loci potentially associated with POI in
Chinese, Korean, and Dutch women. However, in each it was difﬁcult
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to implicate speciﬁc novel genes, and in none did signiﬁcance exceed
1026; positive ﬁndings were not always replicated. The most likely ex-
planation for these data is limitation based on small sample size. In no
study did sample number exceed 1000, thus lacking statistical power suf-
ﬁcient to detect amodest associationwhen evaluating hundreds of thou-
sands of SNPs. That POI is a rarer condition than polycystic ovary
syndrome or endometriosis makes it difﬁcult to accrue the requisite
sample size possible in studying those disorders (Uno et al., 2010;
Chen et al., 2011a; Shi et al., 2012).
GWAS involving family linkage analysis
Table IV includes two genome-wide association linkage studies involving
single extended families. In a Dutch POI family subjected to a genome-
wide linkage scan 5q14.1-q15 was found to be a susceptibility region
(Oldenburg et al., 2008). Caburet et al. (2012) performed genome-wide
linkage and homozygosity analysis in a large consanguineous
Middle-Eastern POI-affected family showing autosomal inheritance.
Tworegions—7p21.1-p15.3 and7q21.3-q22.2—were identiﬁed as can-
didate regions by homozygosity mapping. However, sequencing the
three most plausible candidate genes in this region—DLX5, DLX6 and
DSS1—failed to reveal mutations.
GWAS involving age of menopause
Insights derived from shared genetic susceptibility between POI and
either age at natural menopause (AANM) or early menopause (EM) re-
present another potential path identifying novel entry points for unravel-
ing genetic mechanism involved in POI. Thus, we gathered 36 SNPs
shown from previous GWAS studies seeking SNPs associated with
AANM or EM, plus 3 additional SNPs in ESR1 and 2 additional SNPs in
PTHB1. Differential association was then sought in 371 POI and 800
controls, all of Chinese Han origin (Qin et al., 2012c). Three SNPs,
rs2278493 in hexokinase 3 (HK3), rs2234693 in estrogen receptor 1
(ESR1) and rs12611091 in BR serine/threonine kinase 1 (BRSK1),
showed nominally signiﬁcant association with POI. Thus, a plausible re-
lationship could exist between POI and ESR1, BRSK1, HK3.
Cytogenomic studies (CNV)
There is increasing interest toward whole genome studies based on
CNVs. Using CGH, one can efﬁciently search for small duplications or
deletions potentially associated with a complex trait (such as POI).
The purpose of identifying CNVs is that they may contain or be linked
to a causative gene for the disorder studied. Seven array CGH studies
have identiﬁed CNVs associated with POI (Supplementary Table SV).
In 2009, Aboura et al. (2009) reported that 8 previously knownCNVs
in 99 POI French patients located near 5 potential candidate genes—
Dynein, axonemal, heavy chain 5 (DNAH5),NLR family, apoptosis inhibi-
tory protein (NAIP), Dual speciﬁcity phosphatase 22 (DUSP22), Nuclear
protein, transcriptional regulator, 1 (NUPR1), and AKT1. However, this
and all other CGH studies have the major pitfall of usually lacking infor-
mation on parents. A large, de novo, CNV deletion is more likely to be
pathogenic than an inherited CNV. Another array CGH study involving
74 German patients with POI or ovarian dysgenesis identiﬁed 44
losses or gains at autosomes and X chromosome that might explain
POI (Ledig et al., 2010). McGuire et al. (2011) identiﬁed 17 novel micro-
duplications and 7 novel microdeletions among 89 POI patients, all but
one located at autosomes. Included were two novel microdeletions
causing haploinsufﬁciency for Synaptonemal complex central element
protein 1 (SYCE1) and Cytoplasmic polyadenylation element binding
protein 1 (CPEB1), genes known to cause ovarian failure in knockout
mouse models (Bolcun-Filas et al., 2009; Novoa et al., 2010). Recently,
.............................................................................................................................................................................................
Table IV Genome-wide association studies for POI.
Kang et al. (2008) Knauff et al.
(2009)
Qin et al.
(2012b)
Pyun et al. (2012) Oldenburg
et al. (2008)
Caburet et al. (2012)
Ethnicity Korean Caucasian
(Dutch)
Chinese Korean Dutch Middle-Eastern
Discovery set
No. of cases 24 99 391 24 10 5
No. of controls 24 181 895 24 5 4
Associations in
discovery set
PTHB1 at 7p14 showed
strongest association.
Ht1 GAAAG:
POI-susceptible
haplotype;
Ht2 TGTGC:
POI-resistant haplotype.
rs246246
mapped to
ADAMTS19
intron
8q22.3
(1026)
22 SNPs in LAMC1
associated with POI
Susceptible
locus:
5q14.1-q15
Susceptible loci:
7p21.1-15.3, 7q21.3-22.2
Replication set
No. of cases 101 60 400 98 – –
No. of controls 87 90 800 218 – –
Results of
replication set
PTHB1 associated with
POI; Ht1 confers
susceptibility to POI.
Association not
conﬁrmed.
Frequencies of 9 SNPs
and 1 haplotype were
higher in POI than in
control.
– Sequencing three candidate
genesDLX5,DLX6 andDSS1
did not reveal causal
mutations
PTHB1: Bardet–Biedl syndrome 9 (BBS9); ADAMTS19: ADAM metallopeptidase with thrombospondin type 1 motif, 19; LAMC1: laminin, gamma 1; DLX5, 6: distal-less homeobox 5
and 6; DSS1: split hand/foot malformation (ectrodactyly) type 1.
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a high-resolution array CGH identiﬁed eleven unique CNVs in 11
patients with POI. Among these CNVs, a tandem duplication of
475 bp containing 3 NOBOX-binding elements and an E-box important
for GDF9 gene regulation in the promoter of GDF9 is likely causative of
POI (Norling et al., 2014).
Using a completeXchromosome tiling path array,Quilter et al. (2010)
found15novel discreteXchromosome intervals in 20/42 (48%)women
with POI in the UK. However, in patients from New Zealand, Dudding
et al. (2010) detected only two microduplications (Xp22.33 and
Xq13.3) in a low frequency of 4%. Knauff et al. (2011) found one CNV
in Xq21.3 to be associated with POI, speciﬁcally in a region where Pro-
tocadherin 11 X-linked (PCDH11X) and TGFB-induced factor homeo-
box 2-like, X-linked (TGIF2LX) are located. Interestingly, no deletions
were found inother regions, several consideredon thebasis of traditional
cytogenetic studies to be pivotal (Simpson and Rajkovic, 1999).
Differing array CGH platforms and deﬁnitions for pathogenicity prob-
ablyexplain someof thediscrepant results among the abovestudies.Also
problematic is the limited sample size and lack of parental studies to
exclude aCNVostensibly associatedwith POImerely having been trans-
mitted from a normal mother.
WES
Low prevalence and impaired fecundity resulting in limited numbers of
POI pedigrees without associated somatic anomalies (non-syndromic)
has led to increasing application of WES, another agnostic approach.
WES has identiﬁed several genes in POI not previously anticipated.
In POI associated with somatic features, causative perturbations have
been found by WES for HSB17B4, LARS2, CLPP and C10orf2 in Perrault
syndrome (Pierce et al., 2010, 2013; Jenkinson et al., 2013;Morino
et al., 2014) (detailed in ‘Mitochondrial Genes Causing POI’ section
and Table V). Up to the present, there have been six WES conducted
in non-syndromic POI pedigrees. Interestingly, almost all plausible candi-
date genes identiﬁedwere involved inmeiosis andDNArepair (Table V).
ATP-dependent DNA helicase homolog (HFM1) (1p22.2). HFM1, a meiotic
gene encoding DNA helicase preferentially expressed in germ-line
tissues such as testis and ovary, is necessary for homologous recombin-
ation and synapsis duringmeiosis (Tanaka et al., 2006).Hfm12/2 female
mice had signiﬁcantly reduced ovaries and follicle numbers and an in-
crease in stromal cells (Guiraldelli et al., 2013). The recent report by
Wang et al. (2014a) identiﬁed a compound heterozygous mutation
(c.1686-1G.C and c.2651T.G, p.I884S) in the HFM1 gene in two
affected Chinese sisters. Screening for HFM1 mutations in a cohort of
69 Chinese women with sporadic POI identiﬁed another patient with
compound heterozygous mutations (c.2206G.A, p.G736S and
c.3929_3930 delinsG, p.P1310R fs*41). These variants were not found
in 316 matched controls or databases.
Minichromosome maintenance complex component 8 and 9 (MCM8,
20p12.3; MCM9, 6q22.31). MCM8 and MCM9, recently discovered
members of the highly conserved mini-chromosome maintenance pro-
teins (MCM), are genes implicated in homologous recombination and
repair of double-stranded DNA breaks. The MCM8/MCM9 complex
is required for the resolution of dsDNA breaks that occur during hom-
ologous recombination in pachytene of meiosis I. Failure to resolve
breaks predictably leads to oocyte death and small or absent ovaries.
Mcm8 and Mcm9-deﬁcient mice are infertile and have small gonads
due to germ cell depletion (Lutzmann et al., 2012). Recently, Rajkovic
and colleagues (AlAsiri et al., 2015;Wood-Trageser et al., 2014) discov-
ered homozygous mutations inMCM8 andMCM9 genes in consanguin-
eous families with POI (primary amenorrhea), using WES. One of the
two mutations found inMCM9 is c.1732+2T.C, which resulted in ab-
normal alternative splicing and truncated formsofMCM9 that are unable
to be recruited to sites ofDNAdamage. The othermutation c.394C.T
(p.R132*) results in loss of function of MCM9. It is suspected that pref-
erential sensitivity of germline meiosis to MCM9 functional deﬁciency
and compromised DNA repair in the somatic component most likely
account for the ovarian failure and short stature. A homozygous
mutant c.446C.G (p.P149R) found inMCM8 inhibited recruitment of
MCM8 to sites of DNA damage and led to genomic instability. ASNP
rs16991615 in MCM8 was also found associated with the age of
natural menopause in the GWAS previously discussed (Chen et al.,
2012). The role the novel MCM8/MCM9 pathway plays in women
with idiopathic POI needs to be explored further.
Stromal antigen 3 (STAG3) (7q22.1). STAG3 encodes a subunit of cohesin,
a large protein complex that is essential for proper pairing and segrega-
tionof chromosomesduringmeiosis.Ahomozygous frameshiftmutation
resulting from a 1-bp deletion (c.968delC, p.F187fs*7) in STAG3 was
identiﬁed in a highly consanguineous Palestinian pedigree; in which a
10-Mb region on 7q21.3–22.2 and a 3-Mb region on 7p21.1–15.3 had
beenpreviously identiﬁed to showsigniﬁcant linkagewith thePOIpheno-
type (Caburet et al., 2012, 2014). Deﬁciency of Stag3 in female mice
results in severe and early ovarian dysgenesis, with distinctive lack of
oocytes and ovarian follicles. Early meiotic arrest and the centromeric
chromosomal cohesion defects were observed in Stag32/2fetal
oocytes providing further evidence that Stag3 is essential for assembly
of the meiotic cohesin ring and the synaptonemal complex (Caburet
et al., 2014).
Synaptonemal complex central element 1 (SYCE1) (10q26.3). The SYCE1
gene encodes a component of the synaptonemal complex where
paired chromosome homologs closely associate in meiosis (synapsis)
before crossover. Syce12/2 mice were infertile with smaller gonads,
and showed loss of follicles in ovaries and postmeiotic cells in testis.
Early meiosis arrest at prophase\xE2\x85followed by cell apoptosis
could explain the phenotype (Bolcun-Filas et al., 2009). Different micro-
deletions of SYCE1 have also been reported in Caucasian and Chinese
POI patients (McGuire et al., 2011; Zhen et al., 2013). In a consanguin-
eous Israeli Arab family, a homozygous nonsense mutation
(c.613C.T, p.Q205*) in SYCE1 was identiﬁed in two sisters with
primary amenorrhea, presumably inherited in autosomal recessive
fashion (de Vries et al., 2014).
Eukaryotic translation initiation factor 4E nuclear import factor 1 (eIF4ENIF1)
(22q11.2). eIF4ENIF1, a transport protein, plays an important role in
repressing translation through eIF4E. Both genes appear to play import-
ant roles in ovarian germ cell development (Villaescusa et al., 2006). A
heterozygous nonsensemutation (c.1286C.G, p.S429*) was identiﬁed
in eIF4ENIF1, segregatingwith ovarian insufﬁciency (menopause age 29–
35 years) in a large French Canadian family. No additional mutations
were identiﬁed in eIF4ENIF1 or eIF4E in 38 unrelated women with iso-
lated POI. Haploinsufﬁciency or nuclear sequestration might disrupt
the development of a normal oocyte complement (de Vries et al., 2014).
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The whole exome studies in familial POI mentioned above mainly
involve genes crucial during meiosis, such as generating and repairing
DSBs, chromosome synapsis and recombination, and sister chromatid
cohesion. This implies that perturbation of genes encoding proteins
that regulate meiosis can result in autosomal recessive primary ovarian
insufﬁciency in humans. Despite some negative candidate gene results
with meiotic genes (DMC1, SPO11 and MSH4) in POI, WES results still
provide reasons to pursue other genes participating in meiosis and
DNA repair in ubiquitous pathways.
NGS
Future studies on targeted candidate genes of POI can be anticipated
using NGS. A recent abstract (Fonseca et al., 2015) reported a study
of 12 POI cases having non-syndromic POI and 176 control women
whose menopause had occurred after age 50 years. A further 345
women from the same ethnic origin were stated to be recruited to
assess allele frequency for potentially deleterious sequence variants. In
the 12 POF cases, complete coding regions of 70 candidate genes
were fully sequenced with mutations claimed in ADAMTS19, BMPR2
and LHCGR genes. Full details are awaited.
Regulatory genes and networks
Seeking POF genes has to date largely focused on coding variants, pre-
suming plausible protein disruption. However, only 1.5% of the
genome is protein-coding. Indeed, many POF-associated variants in
whole genome studiesmapwithin, or in linkage disequilibrium to, intron-
ic or intergenic regions; thus, these regions likely contain causative regu-
latory genes or networks. In our own POI GWAS, for example, ‘gene
desert’ 8q22.3 was the region of most signiﬁcance by association (Qin
et al., 2012b).
Non-coding variants must be more robustly interrogated. Perturba-
tions sought should include involving non-coding RNA (microRNA
[miRNA], long non-coding RNA [lncRNA]), disruption or creation of al-
ternative splicing or transcription factor-binding sites, and epigenetic
modiﬁcations (DNA methylation patterns, chromatin modiﬁcation).
Large epigenetic consortia, such as ENCODE (http://genome.ucsc.
edu/ENCODE/), Roadmap (http://www.roadmapepigenomics.org/)
and iHEC (http://www.ihec-epigenomes.org/) point to approaches
used to characterize the regulatory landscape of susceptibility regions
for speciﬁc cell types. Unfortunately, ENCODE (Birney et al., 2007;
ENCODE Project Consortium, 2012; Stamatoyannopoulos et al.,
.............................................................................................................................................................................................
Table V Whole-exome sequencing for syndromic or isolated POI.
Gene Location Mutation Function Compound
Het/Homo/Het
Reference
HSB17B4 5q21 c.650A.G (p.Y217C);
c.1704T.A (p.Y568X)
Reduced expression with mutant protein Compound
heterozygous
Pierce et al. (2010)
CLPP 19p13.3 c.433A.C (p.T145P), Alter the structure of the CLPP barrel chamber that
captures unfolded proteins and exposes them to
proteolysis
Homozygous Jenkinson et al. (2013)
c.440G.C (p.C147S)
c.270+4A.G Weakens donor splice-site function
LARS2 3p21.3 c.1565C.A (p.T522N) Partially functional in Yeast complementation assay Homozygous Pierce et al. (2013)
c.1077delT;
c.1886C.T (p.T629M)
Nonfunctional in Yeast complementation assay Compound
heterozygous
C10orf2 10q24 c.1172G.A (p.R391H)
c.1754A.G (p.N585S)
Affect interactions of the linker domain
Likely affect enzyme activity
Compound
heterozygous
Morino et al. (2014)
c.1321T.G (p.W441G)
c.1519G.A (p.V507I)
Affect interactions of the linker domain Compound
heterozygous
HFM1 1p22.2 c.1686-1G.C
c.2651T.G (p.I884S)
Compound
heterozygous
Wang et al. (2014a)
c.2206G.A (p.G736S);
c.3929_3930 delinsG,
(p.P1310R fs*41)
Compound
heterozygous
MCM9 6q22.31 c.1732+2T.C Abnormal splicing and truncated protein that are
unable to be recruited to sites necessary for DNA
damage
Homozygous Wood-Trageser et al.
(2014)
c.394C.T (p.R132*) Repair of chromosomebreaks impaired in lymphocytes Homozygous
STAG3 7q22.1 c.968delC (p.F187fs*7) Homozygous Caburet et al. (2014)
SYCE1 10q26.3 c.613C.T (p.Q205*) Homozygous de Vries et al. (2014)
MCM8 20p12.3 c.446C.G (p.P149R) Impedes the repair of MMC-induced chromosomal
breaks; inhibits MCM8 recruitment to sites of DNA
damage; impairsDNAbinding ability at theN-terminus
Homozygous AlAsiri et al. (2015)
eIF4ENIF1 22q11.2 c.1286C.G (p.S429*) Heterozygous Kasippillai et al. (2013)
HSD17B4: Hydroxysteroid (17-beta) dehydrogenase 4; CLPP: Caseinolytic mitochondrial matrix peptidase proteolytic subunit; LARS2: leucyl-tRNA synthetase 2, mitochondrial;
C10orf2: Chromosome 10 open reading frame 2; HFM1: ATP-dependentDNAhelicase homolog; MCM8,MCM9:minichromosomemaintenance complex component 8 and 9; STAG3:
stromal antigen 3; SYCE1: synaptonemal complex central element; eIF4ENIF1: eukaryotic translation initiation factor 4E nuclear import factor 1.
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2012) bypassed the reproductive track (males and females), and thus an
ovarian ENCODE does not yet exist.
In order to generate the reproductive ENCODE, human ovarian
tissue of speciﬁc cell types must be studied. Then, differences in regula-
tory genes between affected and normal individuals can be determined.
Massive parallel sequencing using RNA-seq, orMethyl-seqwill facilitate a
systematic study of the transcriptome in ovaries in relation to genotypes
and variants in POI. Chromatin immunoprecipitation followed by se-
quencing (ChIP-Seq) andRNA-Seq can also help identify novel transcrip-
tional and epigenetic regions and, hence, mechanisms that potentially
underlie POI. To analyze the complete proteomes and quantiﬁcation
of post-translational modiﬁcations, mass spectrometry would be the
most attractive approach.
Having accumulated the requisite information, network and pathway-
based analyses of assembled datasets can be assembled using systems
biology approaches. Cascades of transcriptional regulation can be eval-
uated simultaneously, identifying overlap among genes or putative net-
works that currently constrain key variables in model systems.
The ultimate proof that an identiﬁed variant has a pathological effect
traditionally relies on constitutive or conditional knock in/out or cell
lineswith amutation signature. Increasingly, other approacheswill be uti-
lized. Patient-speciﬁc induced pluripotent stem cells (iPSCs) lines might
offer an individually targeted genetic model system to identify and ma-
nipulate pathologic pathway. Use of iPSCs should be of particular value
in assessing regulatory genes, which may have a quantitative deleterious
effect rather than ‘all or none’ qualitative effect, observed or assumed, in
missense or nonsense protein-coding mutations.
Conclusion: current status of
genes causing POI
The POI—causative genes surveyed and found to date allow us to reach
several conclusions.
First, many genes have emerged as POI candidates (Fig. 1), but in non-
syndromicPOIonly aminority havebeenprovenequivocally causativeby
functional validation. These include BMP15, PGRMC1, and FMR1 premu-
tation on the X chromosome and on autosomes GDF9, FIGLA, FSHR,
NOBOX,NR5A1,NANOS3, STAG3, SYCE1,MCM8/9 andHFM1.Noper-
turbations have been found in a dozen other plausible candidates for
which murine knockouts show ovarian failure, but this may simply
reﬂect small sample sizes or interrogation restricted to a single ethnic
group.
Second, notable differences in frequency exist among different popula-
tions. This is predictable for any genetic condition, and in POI this has
already been observed in FSHR, BMP15, NOBOX, FOXL2, TGFBR3,
CDKN1B and FOXO3A (Supplementary Table SII). Future genetic studies
should involve different ethnic groups and larger sample sizes. Clinically,
caution should apply when counseling on the basis of data derived from
an ethnic group different from that of the counseled individual.
Third, causative POI genes are increasingly being shown not only to be
restricted to expression in ovaries but also expressedubiquitously. True,
POF5 (NOBOX) and POF6 (FIGLA) are restricted to the ovaries.
However, PTEN is a major regulator of the PI3K pathway involved in sys-
temic cell proliferation, survival, migration and metabolism. PTEN also
plays a vital role in the activation of primordial follicles. The spectrum
of candidate genes potentially causing POI is being enriched.
Fourth, many genes that currently appear isolated in function actually
maybe interrelatedwithin yet tobedeﬁnedpathways. It is logical to strat-
ify by gene function inostensibly distinct systems: endocrine, folliculogen-
esis, cell cycle, meiosis, mitochondrial, as examples. More difﬁcult are
gene-gene or protein-protein interactions, acting in ways not yet
evident. This review thus unavoidably overestimates the role that
protein-coding genesplay to thedetrimentof upstreamanddownstream
regulatory genes. Until recently, exome studies had to be restricted to
sequencing individual candidate genes. Continued advances in sequen-
cing techniques and contemporary bioinformatives will facilitate ﬁnding
additional genes responsible for POI in other portions of the genome.
Figure 1 Schematic representation of chromosomal location of plausible genes associated with primary ovarian insufﬁciency.
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Fifth, elucidating the etiology and molecular basis of POI is of para-
mount importance not only in understanding ovarian physiology but
also in providing genetic counseling and fertility guidance.Once addition-
al variants are detected, it will be increasingly possible to predict the age
of menopause. Women having certain perturbations of POI can be
offered the option of oocyte cryopreservation, with later thawing and
use in assisted reproductive technology at the appropriate age.
Supplementary data
Supplementary data are available at http://humupd.oxfordjournals.org/.
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